Sequelae of Acute Respiratory Distress Syndrome: Interest of Rehabilitation

Abstract

Case Presentation. This clinical case presents the history of a woman hospitalized for acute respiratory distress syndrome (ARDS). A 62-year-old woman, with regular physical activity and no history of respiratory disease or smoking, was hospitalized for moderate ARDS with bilateral pneumonitis. Fourteen days later, she was discharged from the intensive care unit and received respiratory physical therapy. One month later, she experienced exertional dyspnea. A regression of alveolar condensation with persistent sequelae at the pulmonary bases was noted. Three months later, the patient continued daily physical activity with satisfactory tolerance. A reduction in alveolar-capillary transfer, inappropriate hyperventilation upon exercise, and impairment of gas exchanges at maximal effort, suggestive of pulmonary shunt, were demonstrated. At the 6-month evaluation, the patient displayed exertional dyspnea with residual bilateral basal consolidations. Six months later, the dyspnea had ceased. The persistence of bilateral basal interstitial syndrome associated with bronchial dilatation and pleural-based consolidations was noted, as well as a stable impaired alveolar-capillary diffusing capacity. Discussion. Upon discharge from intensive care, pulmonary follow-up should be proposed to ARDS survivors. Moreover, pulmonary function testing at rest and exercise is advised as soon as possible to evaluate the respiratory sequelae. This will help to limit the severity of complications through adapted exercise rehabilitation and then regular physical activity.

COVID-19 and Venous Thromboembolism: A Meta-analysis of Literature Studies

“…This could allow for a better understanding of the pathogenesis of this potentially fatal complication. Moreover, given the unknown long-term outcomes of COVID-19 and the increasing amount of literature data suggesting the presence of residual chronic disability and rehabilitation needs among survivors, [51][52][53][54][55][56][57] it is compelling to identify new biomarkers related to the disease to timely predict its clinical progression and to adequately manage critical patients even after the acute phase (e.g., general ward, rehabilitation centers, and home). 58 In the meantime, in all hospitalized COVID-19 patients, following the WHO and ISTH indications, [59][60][61] prophylactic low-molecular-weight heparin (LMWH) or subcutaneous unfractionated heparin (UFH) should be considered.…”

Hemostatic Changes in Patients with COVID-19: A Meta-Analysis with Meta-Regressions

“…This could allow for the identification of new markers of disease progression. Moreover, considering the unknown long-term outcomes of COVID-19, the growing amount of studies suggesting the presence of a residual chronic disability, and the need of post-discharge rehabilitation after the acute phase [ 130 , 131 , 132 , 133 , 134 , 135 ], it is essential to identify new biomarkers related to the disease for an adequate management of critical patients even after ICU (e.g., general ward, rehabilitation centers, and home). The hypothesis that persistent thromboembolic phenomena may contribute to the long-term outcomes of COVID-19 [ 136 , 137 ] and to the functional sequelae of critically ill patients after discharge [ 12 , 129 ] further supports the urgent need of studies addressing the mechanisms of such hemostatic imbalance in this clinical setting.…”

COVID-19 and venous thromboembolism: current insights and prophylactic strategies

“…This could allow for a better understanding of the mechanisms behind the hypercoagulable state observed in this clinical setting. Moreover, considering the unknown long-term outcomes among survivors of severe SARS-CoV-2 infection and the risk of functional disability following ARDS [31][32][33][34][35][36], it is compelling to identify new biomarkers of disease severity in order to timely predict the clinical progression of this condition.…”